fda compounding semaglutide enforcement news today 2025 is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger to protect patients from unverified FDA issued 25 warning letters
Description
Wichita, KS.
Long half-life (~6 days)
These signaling cascades influence transcription factors, metabolic enzymes, and cellular energy pathways
GLP1 adoption is expanding, but a startstop user base is accelerating existing shifts in how consumers eat and how food brands innovate, according to Numerator.
